Lupkynis FDA Approval History
Last updated by Judith Stewart, BPharm on March 4, 2021.
FDA Approved: Yes (First approved January 22, 2021)
Brand name: Lupkynis
Generic name: voclosporin
Dosage form: Capsules
Company: Aurinia Pharmaceuticals Inc.
Treatment for: Lupus Nephritis
Lupkynis (voclosporin) is a calcineurin-inhibitor immunosuppressant indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN).
Development Timeline for Lupkynis
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.